Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 1,671 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 1,671 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,500,056.64. This trade represents a 0.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.

Centessa Pharmaceuticals Trading Down 6.3 %

Centessa Pharmaceuticals stock opened at $17.04 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 52 week low of $5.58 and a 52 week high of $18.74. The stock has a fifty day moving average of $16.09 and a 200-day moving average of $12.38.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CNTA. Acadian Asset Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $330,000. EntryPoint Capital LLC bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $109,000. Price T Rowe Associates Inc. MD boosted its position in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares in the last quarter. First Light Asset Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $33,923,000. Finally, Artal Group S.A. boosted its position in shares of Centessa Pharmaceuticals by 39.5% during the 1st quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock valued at $15,961,000 after purchasing an additional 400,000 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on CNTA. Jefferies Financial Group lifted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.